title: Comparison between Three Promising ß-emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease.
abstract: Radionuclide therapy is increasingly seen as a promising option to target minimal residual disease. Copper-67, scandium-47 and terbium-161 have a medium-energy β(-) emission which is similar to that of lutetium-177, but offer the advantage of having diagnostic partner isotopes suitable for pretreatment imaging. The aim of this study was to compare the efficacy of (67)Cu, (47)Sc and (161)Tb to irradiate small tumors.
  
  
  
  The absorbed dose deriving from a homogeneous distribution of (67)Cu, (47)Sc or (161)Tb in water-density spheres was calculated with the Monte Carlo code CELLDOSE. The diameters of the spheres ranged from 5 mm to 10 µm, thus simulating micrometastases or single tumor cells. All electron emissions, including β(-) spectra, Auger and conversion electrons were taken into account. Because these radionuclides differ in electron energy per decay, the simulations were run assuming that 1 MeV was released per µm(3), which would result in a dose of 160 Gy if totally absorbed.
  
  
  
  The absorbed dose was similar for the three radionuclides in the 5-mm sphere (146-149 Gy), but decreased differently in smaller spheres. In particular, (161)Tb delivered higher doses compared to the other radionuclides. For instance, in the 100-µm sphere, the absorbed dose was 24.1 Gy with (67)Cu, 14.8 Gy with (47)Sc and 44.5 Gy with (161)Tb. Auger and conversion electrons accounted for 71% of (161)Tb dose. The largest dose differences were found in cell-sized spheres. In the 10-µm sphere, the dose delivered by (161)Tb was 4.1 times higher than that from (67)Cu and 8.1 times that from (47)Sc.
  
  
  
  (161)Tb can effectively irradiate small tumors thanks to its decay spectrum that combines medium-energy β(-) emission and low-energy conversion and Auger electrons. Therefore (161)Tb might be a better candidate than (67)Cu and (47)Sc for treating minimal residual disease in a clinical setting.
authors.affiliation: 1. Université de Bordeaux, CNRS/IN2P3, Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), France;
authors.forename: Christophe
authors.initials: C
authors.lastname: Champion
authors.affiliation: 1. Université de Bordeaux, CNRS/IN2P3, Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), France;
authors.forename: Michele A
authors.initials: MA
authors.lastname: Quinto
authors.affiliation: 2. Service de Médecine Nucléaire - CHU de Bordeaux; UMR-CNRS 5287; LabEx TRAIL; Université de Bordeaux, FRANCE.
authors.forename: Clément
authors.initials: C
authors.lastname: Morgat
authors.affiliation: 2. Service de Médecine Nucléaire - CHU de Bordeaux; UMR-CNRS 5287; LabEx TRAIL; Université de Bordeaux, FRANCE.
authors.forename: Paolo
authors.initials: P
authors.lastname: Zanotti-Fregonara
authors.affiliation: 2. Service de Médecine Nucléaire - CHU de Bordeaux; UMR-CNRS 5287; LabEx TRAIL; Université de Bordeaux, FRANCE.
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
mesh_terms: D003198:Computer Simulation; D003301:Copper Radioisotopes / Q000494:pharmacology; D018365:Neoplasm, Residual / Q000532:radiotherapy*; D009369:Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000494:pharmacology*; D012538:Scandium / Q000494:pharmacology; D013725:Terbium / Q000494:pharmacology
chemical_list: D003301:Copper Radioisotopes; D011868:Radioisotopes; D013725:Terbium; D012538:Scandium
keywords: Dose; copper-67; lutetium-177.; micrometastases; minimal residual disease; radionuclide therapy; scandium-47; terbium-161